Pénzváltó et al. have performed a research focused on identifying resistance mechanisms against tyrosine kinase inhibitors (sunitinib, erlotinib, lapatinib, sorafenib, and gefitinib at the clinically administered doses), targeting the ErbB/RAS pathway in 45 cancer cell lines (also in renal cell carcinoma, as this pathway was often targeted in the latest anti-RCC therapy) (82). Here, EGFR is linked to renal cell carcinoma.